Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with limited systemic treatment options, in part due to a lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and amplification of human epidermal growth factor receptor 2 (HER2) [1, 2]. This evidence concerns the gene ESR1 and triple-negative breast carcinoma.